Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis

NCT01264770 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01264770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01264770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2011
Completion date
August 31, 2013
Enrollment
644 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis